The medical technology landscape in 2026 is defined by a paradigm shift from pandemic-era stabilisation to a focused era of precision consolidation. This period represents the maturation of several long-term technological trajectories, most notably artificial intelligence, neurotechnology, and minimally invasive surgical platforms, converging with a significant recalibration of capital markets and regulatory frameworks. As the industry navigates a complex macroeconomic enviro

The global surgical robotics landscape is undergoing a structural metamorphosis, transitioning from a category defined by venture-backed pioneerism to one increasingly governed by the industrial logic of private equity and large-cap consolidation. While the initial era of robotic-assisted surgery (RAS) was dominated by the "Intuitive Playbook", a high-margin, capital-intensive model focused on soft-tissue dominance, the 2026 horizon indicates a significant diversification of